Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2001
Business Overview: The company manufactures and tests products in research centers in the U.S., U.K., and Germany, selling globally through direct catalog and distributor channels. The company recently completed an initial public offering (IPO) in December 2000 and exercised an over-allotment option in January 2001.
Key Financial Metrics
| Metric | Q1 2001 | Q1 2000 |
|---|---|---|
| Revenues | $8,607,000 | $7,068,000 |
| Gross Profit | $4,161,000 | $3,438,000 |
| Gross Margin | 48.4% | 48.6% |
| Operating Income | $518,000 | $1,185,000 |
| Net Income | $272,000 | $(4,367,000) |
| Diluted EPS | $0.01 | $(0.76) |
| Cash and Equivalents (End of Period) | $42,388,000 | $2,499,000 |
| Operating Cash Flow | $1,569,000 | $600,000 |
| Long-Term Debt | $0 | $1,000 |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 22% ($1.5 million) year-over-year. On a constant currency basis, revenue growth was 29%. Growth was driven by $1.2 million in U.S./Canada sales and $0.3 million from new products in the U.K.
- Profitability Turnaround: The company reported a net income of $272,000 compared to a net loss of $4.367 million in the prior year. This reversal was primarily due to the elimination of a $4.9 million non-cash common stock warrant interest expense recorded in Q1 2000.
- Expense Increases: Operating expenses rose significantly due to the transition to a public company. General and administrative expenses increased 40% (partially due to legal fees regarding the Harvard University lawsuit), and sales and marketing expenses increased 40% due to added personnel.
- Liquidity Position: Cash and cash equivalents increased by $6.6 million to $42.4 million, driven by the exercise of the IPO over-allotment option which generated approximately $5.5 million in net proceeds.
- Debt Elimination: Following the IPO in December 2000, the company repaid all short-term and long-term debt and redeemed all preferred stock. As of March 31, 2001, the company had no long-term debt.
Outlook, Risks, and Unusual Items
- Legal Proceedings: Harvard University sued the company in December 2000 alleging trademark infringement regarding the names "Harvard Bioscience" and "Harvard Apparatus." In April 2001, the court denied a preliminary injunction but ordered the company not to use the name "Harvard" in crimson or a specific font. Management believes the claims are without merit and does not expect a material adverse effect, though litigation expenses may be significant.
- Subsequent Acquisition: On May 1, 2001, the company acquired substantially all assets of Warner Instrument Corporation for $2.6 million in cash.
- Stock Compensation: The company recorded $0.8 million in stock compensation expense for the quarter and expects to recognize an additional $4.4 million over the remaining vesting life of options.
- Foreign Currency Risk: The company incurred a $206,000 foreign currency loss due to dollar-denominated debt in a foreign subsidiary. Management currently manages risk by matching assets and liabilities but may enter into hedging contracts in the future.
- Capital Requirements: Management expects current cash and operating cash flows to be sufficient for at least two years. However, additional capital may be required for accelerated product development or acquisitions, which could dilute existing shareholders.
Investor Verification Checklist
- Verify the status and potential financial impact of the ongoing trademark litigation with Harvard University.
- Confirm the integration and financial performance of the Warner Instrument Corporation acquisition completed in May 2001.
- Monitor the burn rate of the $42.4 million cash balance against the projected two-year runway, especially given increased operating expenses.
- Review the amortization schedule for the $4.4 million of future stock compensation expense.
- Assess the impact of foreign currency fluctuations on future margins, given the lack of historical hedging.